

December 16, 2022  
SBI ALApromo Co., Ltd.

**Notice Regarding Succession of Supplement Business of SBI Pharmaceuticals**

SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; CEO: Yasushi Takezaki; hereinafter “SBI ALApromo”), a subsidiary of SBI Holdings, Inc., engaged in manufacturing and sales of health food and cosmetics using 5-aminolevulinic acid phosphate (“5-ALA”)(\*1) has resolved today at the Board of Directors meeting to succeed the supplement business by way of absorption-type company split from SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; hereinafter “SBI Pharmaceuticals”), setting February 21, 2023 (plan) as the effective date. After this absorption-type company split, SBI ALApromo will be in charge of all the supplement business-related business.

While SBI ALApromo has been engaged in supplement business with its own brand of food with functional claims, etc., it will also focus on the development of products for brands of other companies. At the same time, SBI ALApromo will facilitate business development toward international markets, such as by collaborating with the group companies based in Europe and America, in which operates the supplement business utilizing 5-ALA.

■ Schedule of absorption-type company split

Date of execution of agreement: December 16, 2022

Effective date (plan): February 21, 2023

We appreciate your continued support to the SBI Group’s pharmaceutical and supplement business related to 5-ALA.

(\*1) 5-aminolevulinic acid phosphate (5-ALA) has been added to the ministry of Health, Labor and Welfare’s “list of Ingredients that are not deemed to be pharmaceuticals unless they are labeled as having pharmaceuticals unless they are labeled as having pharmaceutical efficacies.” It is not a pharmaceutical ingredient.

\*\*\*\*\*

For further information, please contact: SBI ALApromo Co., Ltd. Marketing Department

Tel: +81-3-6229-0092 email: sbiala\_info@sbigroup.co.jp